

Journal of Consulting and Clinical Psychology

A Meta-Analysis of Cognitive-Behavioral Therapy for Alcohol or Other Drug Use Disorders: Treatment Efficacy by Contrast Condition

Molly Magill, Lara Ray, Brian Kiluk, Ariel Hoadley, Michael Bernstein, J. Scott Tonigan, and Kathleen Carroll

Online First Publication, October 10, 2019. <http://dx.doi.org/10.1037/ccp0000447>

CITATION

Magill, M., Ray, L., Kiluk, B., Hoadley, A., Bernstein, M., Tonigan, J. S., & Carroll, K. (2019, October 10). A Meta-Analysis of Cognitive-Behavioral Therapy for Alcohol or Other Drug Use Disorders: Treatment Efficacy by Contrast Condition. *Journal of Consulting and Clinical Psychology*. Advance online publication. <http://dx.doi.org/10.1037/ccp0000447>

A Meta-Analysis of Cognitive-Behavioral Therapy for Alcohol or Other Drug Use Disorders: Treatment Efficacy by Contrast Condition

Molly Magill
Brown University

Lara Ray
University of California, Los Angeles

Brian Kiluk
Yale School of Medicine

Ariel Hoadley and Michael Bernstein
Brown University

J. Scott Tonigan
University of New Mexico

Kathleen Carroll
Yale School of Medicine

Objective: This meta-analysis examined 30 randomized controlled trials (32 study sites; 35 study arms) that tested the efficacy of cognitive-behavioral therapy (CBT) for alcohol or other drug use disorders. The study aim was to provide estimates of efficacy against three levels of experimental contrast (i.e., minimal [$k = 5$]; nonspecific therapy [$k = 11$]; specific therapy [$k = 19$]) for consumption frequency and quantity outcomes at early (1 to 6 months [$k_{es} = 41$]) and late (8+ months [$k_{es} = 26$]) follow-up time points. When pooled effect sizes were statistically heterogeneous, study-level moderators were examined. **Method:** The inverse-variance weighted effect size was calculated for each study and pooled under random effects assumptions. Sensitivity analyses included tests of heterogeneity, study influence, and publication bias. **Results:** CBT in contrast to minimal treatment showed a moderate and significant effect size that was consistent across outcome type and follow-up. When CBT was contrasted with a nonspecific therapy or treatment as usual, treatment effect was statistically significant for consumption frequency and quantity at early, but not late, follow-up. CBT effects in contrast to a specific therapy were consistently nonsignificant across outcomes and follow-up time points. Of 10 pooled effect sizes examined, two showed moderate heterogeneity, but multivariate analyses revealed few systematic predictors of between-study variance. **Conclusions:** The current meta-analysis shows that CBT is more effective than a no treatment, minimal treatment, or nonspecific control. Consistent with findings on other evidence-based therapies, CBT did not show superior efficacy in contrast to another specific modality.

What is the public health significance of this article?

This meta-analysis provides an up-to-date summary of treatment efficacy in cognitive-behavioral therapy (CBT) for alcohol or other drug use disorders. CBT is effective for these conditions with outcomes roughly 15% to 26% better than average outcomes in untreated, or minimally treated, controls.


Keywords: alcohol treatment, cognitive behavioral, drug treatment, meta-analysis, relapse prevention

Supplemental materials: <http://dx.doi.org/10.1037/ccp0000447.supp>

Cognitive-behavioral therapy (CBT) is a leading behavioral approach for intervention with alcohol or other drug use disorders

(Substance Abuse and Mental Health Services Administration, 2014). Despite its widespread application, the last meta-analysis of CBT efficacy for substance use was conducted 10 years ago (i.e., Magill & Ray, 2009). This is a significant gap, given the role meta-analysis plays in guiding clinical practice decisions at both micro (e.g., individual providers) and macro (e.g., community agency administrators, public service funders) levels.

We define CBT as a time-limited, multisession intervention that targets cognitive, affective, and environmental risks for substance use and provides training in coping skills to help an individual achieve and maintain abstinence or harm reduction. Applications in the field are often based on Marlatt and Gordon's (1985) model of relapse prevention, and there are several manuals available for use with alcohol (e.g., Epstein & McCrady, 2009; Kadden et al., 1992; Monti, Abrams, Kadden, & Cooney,

Molly Magill, Center for Alcohol and Addiction Studies, Brown University;  Lara Ray, Department of Psychology, University of California, Los Angeles; Brian Kiluk, Department of Psychiatry, Yale School of Medicine; Ariel Hoadley and Michael Bernstein, Department of Behavioral and Social Sciences, Brown University; J. Scott Tonigan, Department of Psychology, University of New Mexico; Kathleen Carroll, Department of Psychiatry, Yale School of Medicine.

This research is supported by Grant AA026006 from National Institute on Alcohol Abuse and Alcoholism, awarded to Molly Magill.

Correspondence concerning this article should be addressed to Molly Magill, Center for Alcohol and Addiction Studies, Brown University, Box S121-5, Providence, RI 02912. E-mail: molly_magill@brown.edu

1989) or other drug use disorders (e.g., Carroll, 1998). CBT for addictions has a well-established evidence base, but this literature continues to evolve (Carroll & Kiluk, 2017). Further, qualitative reviews have concluded that CBT is more effective than no treatment, but have reported mixed results on key questions such as efficacy over another evidence-based therapy (Longabaugh & Morgenstern, 1999), effect variability by primary drug type (Mastroleo & Monti, 2013; McHugh, Hearon, & Otto, 2010), and the optimal timing of intervention effects (Carroll & Onken, 2005).

In quantitative reviews, Irvin and colleagues (1999) examined 26 experimental and quasi-experimental studies of relapse prevention. They reported a small overall effect size ($r = .14$, $p < .05$) and suggested relapse prevention was more effective for alcohol use disorder than for other substances and when delivered in combination with a pharmacological intervention. A decade later, Magill and Ray (2009) followed up this work with a meta-analysis of 53 experimental CBT studies, reporting a similar overall effect size ($g = .15$, $p < .005$), although findings related to superior effects with alcohol use disorder were not replicated. The latter meta-analysis additionally noted the conservative nature of the overall effect size given the types of contrast conditions in the clinical trials reviewed. Specifically, the effect of CBT over no treatment was large ($g = .79$, $p < .005$), but this type of contrast was rare ($k = 6/53$). In comparison, effects for nonspecific contrasts (i.e., a passive, but time-matched or usual care control condition; e.g., treatment as usual, supportive therapy, drug counseling) and specific contrasts (i.e., another manualized therapy condition; e.g., motivational interviewing, contingency management) were small and more common in the literature ($g = .15$, $p < .005$, $k = 32/53$; $g = .11$, $p < .05$, $k = 17/53$, respectively). To our knowledge, this was the last CBT meta-analysis across substances, or for individual substances, conducted to date.

Given the long-standing use of CBT in addictions care as well as its continued evolution, an up-to-date meta-analysis is needed. Additionally, reviews of cognitive therapy more broadly highlight a need for meta-analytic knowledge on effectiveness with substance-using populations (Butler, Chapman, Forman, & Beck, 2006; Hofmann, Asnaani, Vonk, Sawyer, & Fang, 2012). The present meta-analysis provides an updated assessment of CBT efficacy with alcohol or other drug use disorders and may also offer greater conceptual clarity than past quantitative reviews. Specifically, CBT efficacy when delivered in a stand-alone format, and not combined with another psychosocial (Dutra et al., 2008; Magill & Ray, 2009; McHugh et al., 2010) or pharmacological (Irvin et al., 1999; Magill & Ray, 2009) intervention, was the focus of the present report. These latter topics are worthy of meta-analysis in their own right, and including such studies could obscure effect size estimation for the effect modifying factors of primary interest to this study: (a) CBT efficacy by contrast type (i.e., minimal; nonspecific therapy; specific therapy), (b) CBT efficacy by consumption outcome type (i.e., frequency; quantity), and (c) CBT efficacy at early (i.e., 1 to 6 months posttreatment) and late (i.e., 8+ months posttreatment) follow-ups. Effect estimates were additionally examined for validity and stability in sensitivity analyses (i.e., tests of heterogeneity, study influence, and publication bias).

Method

Primary Study Inclusion

Studies meeting inclusion criteria were English language, peer-reviewed articles published between 1980 and 2018. These were primary outcome reports of randomized controlled trials. All types of experimental control were of interest given the importance of this factor in predicting effect size magnitude in the addictions, mental health, and in psychotherapy more broadly (Imel, Wampold, Miller, & Fleming, 2008; Wampold, 2001; Wampold & Imel, 2015; Wampold et al., 1997). Studies were included if they targeted adult populations (age ≥ 18) meeting *Diagnostic and Statistical Manual of Mental Disorders (DSM)* criteria for an alcohol or other drug use disorder (*DSM-III-R* through *DSM-5*; American Psychiatric Association, 1987, 1994, 2000, 2013) or problematic use (e.g., Saunders, Aasland, Babor, de la Fuente, & Grant, 1993). The treatment must have been identified as either cognitive behavioral or relapse prevention, although some studies were included based on a description of key CBT elements such as functional analysis, avoidance of high risk situations, and/or coping skills training (see Table 1 in the online supplemental material for details). Studies of CBT delivered in either individual or group format were included, but we excluded studies of CBT delivered as an integrative therapy combined with another psychosocial (e.g., cognitive behavioral intervention, mindfulness-based relapse prevention) or pharmacological intervention.

Literature Search

A literature search was conducted through June of 2018 to identify eligible studies for a large-scale, meta-analytic project on CBT in addictions care (National Institute on Alcohol Abuse and Alcoholism, R21AA026006). The first step involved a title, abstract, and keyword search by treatment (“cognitive-behavioral therapy” OR “relapse prevention” OR “coping skills training”) AND outcome (“alcohol” OR “cocaine” OR “methamphetamine” OR “stimulant” OR “opiate” OR “heroin” OR “marijuana” OR “cannabis” OR “illicit drug” OR “substances” OR “dual disorder” OR “polysubstance” OR “dual diagnosis”), AND study terms (“efficacy” OR “randomized controlled trial” OR “randomized clinical trial”) in the PubMed database. Then, a search of the Cochrane Register and EBSCO database (i.e., Medline, PsycARTICLES) was performed, removing duplicates from the results of the PubMed search. Abstract screening occurred by two raters in ABSTRKR (Wallace, Small, Brodley, Lau, & Trikalinos, 2012). A bibliographic search of systematic reviews and meta-analyses of CBT was also performed to identify any candidate studies not identified by the original search methods (Carroll, 1996; Carroll & Kiluk, 2017; Irvin et al., 1999; Longabaugh & Morgenstern, 1999; Magill & Ray, 2009; Mastroleo & Monti, 2013; Miller, Wilbourne, & Hettema, 2003; Prendergast, Podus, Chang, & Urada, 2002). Finally, three studies published between 1980 and 1989 were added during peer review to achieve an overlapping date range with Magill and Ray (2009; i.e., Donovan & Ito, 1988; Jones, Kanfer, & Lanyon, 1982; Kadden, Cooney, Getter, & Litt, 1989). Figure 1 provides a visual representation of study inclusion for the present report on stand-alone CBT efficacy with adult alcohol use disorder (AUD), substance use disorder (SUD), or both; the figure




Figure 1. Flow of primary study inclusion. K/k is defined as number of groups. Cognitive-behavioral therapy (CBT) by, for example, dual diagnosis population, couples or self-help format, or ineligible control condition.

follows QUORUM guidelines (Moher et al., 1999). The final meta-analytic sample comprised $K = 30$ studies, with 32 study sites (i.e., two studies provided two sites each; McAuliffe, 1990; Project MATCH Research Group, 1997), and a total of 5,398 participants.

Primary Study Characteristic Variables

There were several study characteristic variables of interest to this meta-analysis, as a priori effect size modifiers (i.e., subgroup

variables) as well as potential pooled effect variance predictors (i.e., metaregression covariates) in instances of systematic (i.e., vs. random) between-study heterogeneity. Effect size modifiers were (a) contrast condition type (i.e., minimal [e.g., waitlist, brief psychoeducation]; nonspecific therapy [e.g., treatment as usual, supportive therapy, drug counseling]; specific therapy [e.g., motivational interviewing, contingency management]), (b) substance use outcome type (i.e., frequency; quantity), and (c) follow-up time point (early = 1 to 6 months posttreatment; late = 8+ months posttreatment). Study-level descriptors and potential metaregres-

sion covariates were mean age, percentage female participants, percentage White participants, percentage Black participants, percentage Latino/a participants, primary drug outcome (i.e., alcohol, other drug), substance use severity (i.e., dependence, abuse or heavy use), treatment length (i.e., number of planned sessions), treatment delivery (i.e., individual format, group format), study context (i.e., community sample, specialty substance use or mental health clinic, medical setting, college setting, criminal justice setting, other setting), publication country (i.e., United States, other country), use of biological assay outcome measure (i.e., yes, no), and study-level risk-of-bias (Higgins et al., 2011). Data extraction guidelines were detailed in a study codebook available, on request, from Molly Magill. Data were extracted in two independent passes conducted by trained raters (i.e., Ariel Hoadley and Michael Bernstein), and showed a between-rater agreement rate of 95.3%. Final data entry, where disagreement was observed, required a consensus review with Molly Magill.

Primary Study Outcome Variables

The standardized mean difference was used to measure efficacy outcomes in this meta-analysis.¹ Hedges' g includes a correction, f , for a slight upward bias in the estimated population effect (Hedges, 1994).

$$g_i = \frac{M_{ii} - M_{ci}}{s_{pi}} \times [f]$$

$$\text{where } f = 1 - (3/(4 \times df - 1)),$$

$$\text{and } s_{pi} = \frac{\sqrt{(n_{ii} - 1)s_{ii}^2 + (n_{ci} - 1)s_{ci}^2}}{n_{ii} + n_{ci} - 2}$$

Prior to pooling, effect sizes were weighted by the inverse of the estimate variance to allow larger studies more influence on the overall effect size (Hedges & Olkin, 1985). Primary studies typically provided data on more than one outcome; therefore, data for effect size estimation were selected based on a decisional hierarchy in the following order: (a) biological assay measures, (b) measures of frequency or quantity in the form of means and standard deviations, (c) sample proportions, and (d) other outcomes (e.g., diagnostic measures [Addiction Severity Index; McLellan, Luborsky, Woody, & O'Brien, 1980]). When multiple months of follow-up date were provided, the latest time point in two different time intervals was selected (i.e., 1 to 6 months, 8+ months). Effect sizes were reverse scored as needed (e.g., number of days drank) such that a positive effect size indicated a positive treatment outcome. Finally, when univariate outcome data were not reported, test statistics were transformed using available formulae (e.g., Lipsey & Wilson, 2001). When data from publications were insufficient for effect size calculation, raw data were obtained from authors where possible (i.e., Kadden, Litt, Cooney, Kabela, & Getter, 2001; Project MATCH Research Group, 1997). One eligible study was removed due to author nonresponse to data request (Källmén, Sjöberg, & Wennberg, 2003).

Data Analysis

Alcohol and other drug use effect sizes were pooled using a random effects model. In this approach, there is an assumed distribution for the population effect size with both systematic and random sources of variability (Hedges & Vevea, 1998). The sig-

nificance of the Q -test determined whether statistically significant between-study heterogeneity existed within a given pooled estimate and the I^2 provided a percentage heterogeneity estimate, regardless of statistical significance.² When I^2 estimates exceeded 40%, indicating that 40% of the variance in effect sizes was due to systematic variance (Borenstein, Hedges, Higgins, & Rothstein, 2015), a multivariate regression model was used to examine potential effect size moderators. Candidate variables were entered in participant (i.e., age, sex, race, primary drug, substance use severity), implementation, (i.e., treatment length, treatment delivery), and methodological (i.e., study risk-of-bias) blocks. Analyses were conducted with Wilson's (2005) METAREG for maximum likelihood regression (SPSS Version 24.0 [IBM Corp, 2016]), and variables with significant regression coefficients were placed into a final predictive model along with residual variance estimates. Missing variable codes for regression covariates were mean imputed, and a predictor was removed from the x analysis if imputed values reached 20% of total cases (Pigott, 1994). We conducted sensitivity analyses throughout data analysis and considered heterogeneity and moderator analyses as two primary methods for examining effect size validity. Trimmed estimates with influential studies removed (Baujat, Mahé, Pignon, & Hill, 2002) were also provided.³ Finally, to test for potential publication bias, the relationship between error and effect size was assessed using rank correlation (Begg & Mazumdar, 1994) and graphical methods (Egger, Davey Smith, Schneider, & Minder, 1997). Here, small sample-small effect studies are assumed to characterize unpublished research, resulting in a significant and negative relationship, thus an asymmetrical funnel plot, when publication bias is present.

Results

Primary Study Descriptive Characteristics

The sample included 30 randomized trials, with 32 study sites, targeting CBT for adult substance use disorders published between 1982 and 2018. The median sample size was 102 participants with a minimum of 39 (Donovan & Ito, 1988) and a maximum of 952 (Project MATCH Research Group, 1997). The primary substance targets within these clinical trials were alcohol ($k = 15$), marijuana ($k = 3$), opiates ($k = 2$), stimulants ($k = 6$), and polydrug ($k = 6$) use. The samples' mean age was 37 ($SD = 6$), samples were 30% female ($SD = 20\%$) on average, and although report of race and ethnicity were inconsistent, the percentiles were as follows: 68% White ($SD = 38\%$; $k = 31/32$), 36% Black ($SD = 37\%$; $k =$

¹ Effect size magnitude was interpreted using the following benchmarks: 0.2 = small, 0.5 = medium, and 0.8 = large (Cohen, 1988). However, these are generic guidelines and should be considered conservative in the absence of empirically based effect size distributions for adult SUD/AUD samples. For example, Tanner-Smith, Durlak, and Marx (2018) suggested that effect size magnitudes of 0.05, 0.10, and 0.15 approximate the 25th, 50th, and 75th percentiles (respectively) for behavioral outcomes in youth drug prevention.

² I^2 magnitude can be interpreted using the following benchmarks: 0% to 40% "might not be important," 30% to 60% "may represent moderate heterogeneity," 50% to 90% "may represent substantial heterogeneity," 75% to 100% "considerable heterogeneity" (Higgins & Green, 2011).

³ An influential study was defined as any study that, if removed, would change the statistical significance of the pooled effect estimate.

18/32), and 12% Latino/a ($SD = 27\%$; $k = 13/32$). Diagnostically, study inclusion primarily targeted individuals with alcohol or drug dependence (78%). The CBT interventions were 53% individual and 44% group delivered, and one study utilized a mixture of individual and group sessions (McKay et al., 2004). The median number of planned sessions was 12 (range = 6 to 40), and recruitment contexts included specialty substance use or mental health clinics ($k = 18$), community advertising ($k = 11$), and other specialty settings (e.g., college campus, medical setting, criminal justice system; $k = 3$). Study-level risk-of-bias assessment showed 60% of studies were low risk (Higgins et al., 2011). When studies were designated as unclear or high risk, this was typically due to the presence or no report of (a) baseline differences between conditions, (b) differential attrition between conditions, and (c) blinding of outcome assessment. Finally, the majority (72%) of studies were published in the United States. Tables 1 and 2 describe each study with respect to design characteristics, effect sizes, and are separated by early and late follow-up time points, respectively.

CBT Effect by Contrast Type, Outcome Type, and Follow-Up Time Point

CBT in contrast to minimal treatment. Primary study effect sizes were pooled by contrast type and within each subgroup, pooled effect sizes by frequency and quantity outcomes at early (i.e., 1 to 6 months) and late (i.e., 8+ months) follow-ups are provided. Studies with minimal, waitlist, or assessment only contrast conditions comprised a minority of the studies reviewed, and the pooled effect size for frequency outcomes was $g = .58$ (95% CI [.15, 1.01], $p = .009$; $\tau^2 = .11$, $Q > .05$, $I^2 = 59\%$; $k = 4$) at early follow-up and $g = .44$ (95% CI [.02, .86], $p = .039$; $\tau^2 = .00$, $Q > .05$, $I^2 = 0\%$; $k = 2$) at late follow-up. For quantity outcomes at early follow-up, the pooled effect size for two studies was moderate and significant ($g = .67$; 95% CI [.41, .98], $p < .001$; $\tau^2 = .00$, $Q > .05$, $I^2 = 0\%$; $k = 2$), but only one study provided late follow-up quantity data (Kivlahan, Marlatt, Fromme, Coppel, & Williams, 1990). Converting effect estimates to a percentile success rate (U^3 ; Cohen, 1988), the data show 15% to 26% of CBT participants had better outcomes than the median of those in minimal treatment conditions. Analyses by minimal contrast showed no influential studies. Figure 2 shows some asymmetry in the plot of primary studies, by minimal contrast, but rank correlation analyses do not suggest bias due to publication status ($\tau = -.33$, $p = .497$).

CBT in contrast to nonspecific therapy. The second level of contrast included studies that compared CBT to some form of nonspecific therapy such as treatment at usual, supportive therapy, or group drug counseling. The pooled effect size for frequency outcomes at early follow-up was small and statistically significant ($g = .18$; 95% CI [.02, .35], $p = .04$; $\tau^2 = .03$, $Q > .05$, $I^2 = 45\%$; $k = 9$) with a success rate roughly 8% higher than the median within the contrast condition. However, the effect was nonsignificant at late follow-up ($g = .05$; 95% CI [-.09, .19], $p = .492$; $\tau^2 = .00$, $Q > .05$, $I^2 = 0\%$; $k = 7$). For quantity outcomes at early follow-up, the pooled effect was moderate and significant for two studies ($g = .42$; 95% CI [.03, .81], $p = .034$; $\tau^2 = .00$, $Q > .05$, $I^2 = 0\%$), and only one study provided late follow-up quantity data (Kivlahan et al., 1990). Analyses of CBT in contrast to a nonspe-

cific therapy showed three influential studies that, when removed, the overall effect size became nonsignificant ($g_{\text{trimmed}} \sim .07$ to .26). Figure 3 shows the plot of primary studies, by nonspecific contrast, and does not suggest bias due to publication status ($\tau = .36$, $p = .059$).

CBT in contrast to another specific therapy. The third level of contrast included studies that compared CBT to another specific therapy (e.g., motivational interviewing, contingency management). The pooled effect size for frequency outcomes was nonsignificant at early ($g = -.02$; 95% CI [-.12, .08], $p = .740$; $\tau^2 = .01$, $Q > .05$, $I^2 = 14\%$; $k = 16$) and late ($g = -.04$; 95% CI [-.15, .08], $p = .507$; $\tau^2 = .01$, $Q > .05$, $I^2 = 15\%$; $k = 8$) follow-ups. For quantity outcomes, pooled effects were also nonsignificant at early ($g = .01$; 95% CI [-.11, .12], $p = .956$; $\tau^2 = .01$, $Q > .05$, $I^2 = 36\%$; $k = 8$) and late ($g = .01$; 95% CI [-.09, .11], $p = .887$; $\tau^2 = .00$, $Q > .05$, $I^2 = 0\%$; $k = 5$) follow-ups. Analyses of CBT in contrast to another specific therapy showed no influential studies and no evidence of publication bias (see Figure 4; $\tau = .00$, $p = .500$).

Analysis of Heterogeneous Pooled Effect Sizes

Given variability in the types of contrast conditions within this sample of CBT efficacy trials, this meta-analysis did not provide a single pooled effect size to characterize the effect of CBT for adult AUD/SUD. Using a subgroup approach, two out of 10 pooled effect sizes were determined to have sufficient systematic heterogeneity to warrant moderator analyses. Of these two estimates (I^2 range = 45–59%), only one subgroup also contained a sufficient k number of studies to provide variability in the covariates examined.⁴ For heterogeneous effects of CBT on early follow-up use frequency in contrast to a nonspecific therapy ($g = .18$; $Q > .05$, $I^2 = 45\%$; $k = 9$), we used a metaregression approach to conduct random effects moderator analysis. Within this approach, a priori covariates are considered, but residual heterogeneity is also expected and acceptable. Table 3 summarizes findings for the participant, implementation, and methodological models. These analyses yielded largely nonsignificant metaregression estimates, with the exception of client age. For CBT effects on early follow-up use frequency in contrast to a nonspecific therapy, older age was associated with smaller effect sizes ($b = -.072$, $p = .044$).

Discussion

To our knowledge, this is the first meta-analysis of CBT efficacy for adults with alcohol and other drug use disorders conducted in 10 years, despite ongoing research and utilization of the CBT approach. We pooled primary study effect sizes by contrast condition type (i.e., minimal, nonspecific therapy, specific therapy), and then by consumption outcome type (i.e., frequency, quantity) and follow-up time point (i.e., early, late). For the most part ($k = 8/10$), these subgroup estimates showed acceptable homogeneity. This suggests that the selected variables were informative effect size modifiers for the sample of clinical trials reviewed. Meta-analyses of alcohol or other drug treatments generally show effect sizes in the small to moderate range (e.g.,

⁴ For heterogeneous effects of CBT on early follow-up use frequency in contrast to minimal treatment, the sample of primary studies was $k = 4$.

Table 1
Cognitive-Behavioral Therapy Efficacy at Early Follow-Up by Type of Contrast Condition

Author (date)	N ^a	Treatment	Contrast	Drug	Follow-up month	Outcome ^b	Risk of bias ^c	g(SE)
Minimal/waitlist contrast								
Kivlahan et al. (1990)	43	Alcohol skills training	Assessment only	Alcohol	4	Drinks per week	L	.43 (.36)
Lanza et al. (2014)	50	Cognitive-behavioral therapy	Waitlist	Polydrug	6	Rate abstinent	U	.27 (.48)
McAuliffe (1990)—US	88	Relapse prevention	Referral	Opiates	6	Rate abstinent	L	.44 (.26)
McAuliffe (1990)—HK	80	Relapse prevention	Referral	Opiates	6	Rate abstinent	L	.26 (.32)
Stephens et al. (2000)	291	Relapse prevention	Waitlist	Marijuana	4	days used	L	1.01 (.16)
Stephens et al. (2000)	291	Relapse prevention	Waitlist	Marijuana	4	Use per day	L	.75 (.16)
Nonspecific therapy contrast								
Bowen et al. (2014)	183	Relapse prevention	TAU	Polydrug	6	Days used	L	.26 (.16)
Burtscheidt et al. (2002)	80	Coping skills training	Nonspecific support group	Alcohol	6	Rate abstinent	U	.12 (.26)
Kivlahan et al. (1990)	43	Alcohol skills training	Didactic alcohol information	Alcohol	4	Drinks per week	L	.46 (.37)
McKay et al. (1997)	98	Relapse prevention	Group counseling	Polydrug	6	Days used	L	-.14 (.20)
McKay et al. (2004)	257	Relapse prevention	Group counseling	Polydrug	6	Rate abstinent	U	.10 (.13)
McKay et al. (2010)	75	Relapse prevention	TAU	Cocaine	6	Rate relapse	U	.00 (.31)
Monti et al. (1997)	128	Coping skills training	Attention placebo	Cocaine	6	Days used	L	.59 (.20)
Morgenstern et al. (2001)	168	Cognitive-behavioral therapy	TAU	Polydrug	6	Days abstinent	L	.08 (.15)
Papas et al. (2011)	75	Cognitive-behavioral therapy	TAU	Alcohol	3	Days used	L	.72 (.24)
Papas et al. (2011)	75	Cognitive-behavioral therapy	TAU	Alcohol	3	Drinks per day	L	.40 (.23)
Stephens et al. (1994)	212	Relapse prevention	Social support group	Marijuana	6	Days used	U	.01 (.15)
Specific therapy contrast								
Brown et al. (2002)	133	Relapse prevention	12-step facilitation	Polydrug	6	Days to first lapse	L	-.23 (.17)
Budney et al. (2006)	60	Cognitive-behavioral therapy	Contingency management	Marijuana	6	Days used	L	.32 (.30)
Carroll et al. (1991)	42	Relapse prevention	Interpersonal psychotherapy	Cocaine	1	Rate abstinent	H	.53 (.35)
Donovan and Ito (1988)	39	Relapse prevention	Interpersonal process group	Alcohol	6	Days drank	U	.27 (.35)
Heather et al. (2000)	91	Behavioral self-control	Moderation cue exposure	Alcohol	6	Days abstinent	L	-.23 (.23)
Heather et al. (2000)	91	Behavioral self-control	Moderation cue exposure	Alcohol	6	Drinks per day	L	.41 (.23)
Kadden et al. (1989)	96	Coping skills training	Interactional group therapy	Alcohol	6	Days abstinent	U	.00 (.19)
Kadden et al. (2001)	250	Cognitive-behavioral therapy	Interactional group therapy	Alcohol	6	Days abstinent	U	.17 (.18)
Lanza et al. (2014)	50	Cognitive-behavioral therapy	Acceptance and commitment	Polydrug	6	Rate abstinent	U	-.41 (.38)
Litt et al. (2016)	193	Cognitive-behavioral therapy	Network support therapy	Alcohol	6	Days abstinent	L	-.18 (.14)
Litt et al. (2016)	193	Cognitive-behavioral therapy	Network support therapy	Alcohol	6	Heavy use days	L	-.11 (.14)
Maude-Griffin et al. (1998)	128	Cognitive-behavioral therapy	12-step facilitation	Cocaine	4	Rate abstinent	L	.22 (.21)
McKay et al. (2010)	75	Relapse prevention	Contingency management	Cocaine	6	Rate relapse	U	-.22 (.32)
Project MATCH (1997)—outpatient	952	Cognitive-behavioral therapy	Motivational interviewing/12-step facilitation ^d	Alcohol	6	Days abstinent	L	-.05 (.08)
Project MATCH (1997)—outpatient	952	Cognitive-behavioral therapy	Motivational interviewing/12-step facilitation ^d	Alcohol	6	Drinks per day	L	.09 (.08)
Project MATCH (1997)—aftercare	774	Cognitive-behavioral therapy	Motivational interviewing/12-step facilitation ^d	Alcohol	6	Days abstinent	L	-.06 (.09)
Project MATCH (1997)—aftercare	774	Cognitive-behavioral therapy	Motivational interviewing/12-step facilitation ^d	Alcohol	6	Drinks per day	L	-.06 (.09)
Shakeshaft et al. (2002)	295	Cognitive-behavioral therapy	Brief intervention	Alcohol	6	Days heavy use	L	-.05 (.12)
Sitharthan et al. (1997)	42	Cognitive-behavioral therapy	Cue exposure	Alcohol	6	Days used	L	-.61 (.31)
Sitharthan et al. (1997)	42	Cognitive-behavioral therapy	Cue exposure	Alcohol	6	Drinks per day	L	-.66 (.31)
Smout et al. (2010)	104	Cognitive-behavioral therapy	Acceptance and commitment	Methamphetamine	6	Rate relapse	H	-.29 (.50)
Smout et al. (2010)	104	Cognitive-behavioral therapy	Acceptance and commitment	Methamphetamine	6	Grams per month	H	.16 (.20)
Stephens et al. (2000)	291	Relapse prevention	Motivational interviewing	Marijuana	6	Days used	L	.12 (.15)
Stephens et al. (2000)	291	Relapse prevention	Motivational interviewing	Marijuana	6	Use per day	L	.04 (.15)

Note. $k_{\text{effect, sizes}} = 41$. TAU = treatment as usual; US = United States; HK = Hong Kong; L = low risk; U = unclear risk; H = high risk.

^a If an arm of the trial did not contribute an effect contrast, the study-level sample size was adjusted. ^b Negative outcomes such as days used or number of times used per day were reverse-scored such that a positive effect estimate would reflect a positive treatment outcome. ^c Cochran Risk of Bias Tool (Higgins et al., 2011). ^d Active contrasts outcomes were pooled to provide a single estimate per outcome type and follow-up for Project MATCH.

This document is copyrighted by the American Psychological Association or one of its allied publishers. This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.

Table 2
Cognitive-Behavior Therapy Efficacy at Late Follow-Up by Type of Contrast Condition

Author (date)	N ^a	Treatment	Contrast	Drug	Follow-up month	Outcome ^b	Risk of bias ^c	g(SE)
Minimal/waitlist contrast								
Kivlahan et al. (1990)	43	Alcohol skills training	Assessment only	Alcohol	12	Drinks per week	L	.98 (.38)
McAuliffe (1990)—US	88	Relapse prevention	Referral	Opiates	12	Rate abstinent	L	.35 (.27)
McAuliffe (1990)—HK	80	Relapse prevention	Referral	Opiates	12	Rate abstinent	L	.60 (.35)
Nonspecific therapy								
Bowen et al. (2014)	183	Relapse prevention	TAU	Polydrug	12	Days used	L	-.08 (.16)
Burtscheidt et al. (2002)	80	Coping skills training	Nonspecific support group	Alcohol	30	Rate abstinent	U	.30 (.46)
Jones et al. (1982)	45	Alcohol skills training	TAU	Alcohol	12	Days abstinent	U	.82 (.46)
Jones et al. (1982)	45	Alcohol skills training	TAU	Alcohol	12	Mean consumption	U	.85 (.46)
Kivlahan et al. (1990)	43	Alcohol skills training	Didactic alcohol information	Alcohol	12	Drinks per week	L	.75 (.38)
McKay et al. (1997)	98	Relapse prevention	Group counseling	Polydrug	24	Days used	L	.09 (.17)
McKay et al. (2004)	257	Relapse prevention	Group counseling	Polydrug	12	Rate abstinent	U	.13 (.13)
McKay et al. (2010)	75	Relapse prevention	TAU	Cocaine	18	Rate relapse	U	-.13 (.32)
Stephens et al. (1994)	212	Relapse prevention	Social support group	Marijuana	12	Days used	U	-.04 (.15)
Thornton et al. (2003)	291	Behavioral treatment	Facilitative therapy	Polydrug	9	ASI ^e	U	-.04 (.20)
Specific therapy								
Budney et al. (2006)	60	Cognitive-behavioral therapy	Contingency management	Marijuana	12	Days used	L	-.01 (.29)
Dawe et al. (2002)	100	Behavioral self-control	Moderation cue exposure	Alcohol	8	Days used	U	.03 (.22)
Dawe et al. (2002)	100	Behavioral self-control	Moderation cue exposure	Alcohol	8	Days heavy use	U	.22 (.22)
Litt et al. (2016)	193	Cognitive-behavioral therapy	Network support therapy	Alcohol	27	Days abstinent	L	-.14 (.14)
Litt et al. (2016)	193	Cognitive-behavioral therapy	Network support therapy	Alcohol	27	Days heavy use	L	-.03 (.14)
McKay et al. (2010)	75	Relapse prevention	Contingency management	Cocaine	18	Rate relapse	U	-.36 (.33)
Project MATCH (1997)—outpatient	952	Cognitive-behavioral therapy	Motivational interviewing/12-step facilitation ^d	Alcohol	15	Days abstinent	L	-.05 (.08)
Project MATCH (1997)—outpatient	952	Cognitive-behavioral therapy	Motivational interviewing/12-step facilitation ^d	Alcohol	15	Drinks per day	L	.09 (.08)
Project MATCH (1997)—aftercare	774	Cognitive-behavioral therapy	Motivational interviewing/12-step facilitation ^d	Alcohol	15	Days abstinent	L	.09 (.09)
Project MATCH (1997)—aftercare	774	Cognitive-behavioral therapy	Motivational interviewing/12-step facilitation ^d	Alcohol	15	Drinks per day	L	-.11 (.09)
Sandahl et al. (2004)	49	Cognitive-behavioral therapy	Psychodynamic therapy	Alcohol	15	Days abstinent	L	-.64 (.29)
Stephens et al. (2000)	291	Relapse prevention	Motivational interviewing	Marijuana	16	Days used	L	.06 (.16)
Stephens et al. (2000)	291	Relapse prevention	Motivational interviewing	Marijuana	16	Use per day	L	.02 (.16)

Note. $K_{effect\ sizes} = 26$. TAU = treatment as usual; US = United States; HK = Hong Kong; L = low risk; U = unclear risk; H = high risk.

^a If an arm of the trial did not contribute an effect contrast, the study-level sample size was adjusted. ^b Negative outcomes such as days used or number of times used per day were reverse-scored such that a positive effect estimate would reflect a positive treatment outcome. ^c Cochrane Risk of Bias Tool (Higgins et al., 2011). ^d Active contrasts outcomes were pooled to provide a single estimate per outcome type and follow-up for Project MATCH. ^e Addiction Severity Index (McLellan, Luborsky, Woody, & O'Brien, 1980).




Figure 2. Plot of assessment of publication bias. Assessment of bias in cognitive-behavioral therapy (CBT) effect in contrast to a minimal condition. The plot shows some rank order asymmetry, but the rank order correlation shows a nonsignificant relationship between precision and effect size ($\tau = -.33, p > .05$).

Bertholet, Daepfen, Wietlisbach, Fleming, & Burnand, 2005; Lundahl, Kunz, Brownell, Tollefson, & Burke, 2010; Prendergast et al., 2002) and this includes pharmacological treatments (e.g., Fullerton et al., 2014; Maisel, Blodgett, Wilbourne, Humphreys, & Finney, 2013; Streeeton & Whelan, 2001). In the present study, a moderate-to-large and stable (i.e., across outcome type and follow-up time point) effect size was observed for CBT in contrast to no treatment or a minimal treatment comparison (15% to 26% success rate). However, the majority of trials in this review con-

sidered CBT in contrast to an active comparison, either a nonspecific or a specific therapy. In other words, the measure of efficacy in the CBT literature has most often been how well CBT performs in reference to another form of therapy.

In this meta-analysis, we selected two types of treatment outcomes a priori. These were alcohol or other drug use frequency and quantity. The goal was to consider both abstinence and harm reduction, although quantity outcomes ($k_{es} = 19$) were reported less consistently than frequency outcomes ($k_{es} = 47$), and only one




Figure 3. Plot of assessment of publication bias. Assessment of bias in cognitive-behavioral therapy (CBT) effect in contrast to a nonspecific therapy. The plot shows symmetry and the correlation test shows a nonsignificant relationship between precision and effect size ($\tau = .36, p > .05$).




Figure 4. Plot of assessment of publication bias. Assessment of bias in cognitive-behavioral therapy (CBT) effect in contrast to a specific therapy. The plot shows symmetry and the correlation test shows a nonsignificant relationship between precision and effect size ($\tau = .00, p > .05$).

study explicitly targeted substance use moderation (Heather et al., 2000). The current study can thus provide only preliminary data on the broader question of whether CBT is particularly effective for certain types of clinical outcomes. For example, Irvin and colleagues (1999) reported effect sizes for secondary outcomes (e.g., self-efficacy or coping skills) that were more than twice the magnitude of those for substance use. In the present study, CBT

effect sizes for quantity outcomes were larger than frequency outcomes, such as number of abstinent days. This pattern of findings held for minimal and nonspecific therapy contrasts, but caution is warranted due to the relatively smaller number of primary studies contributing quantity outcome effect estimates.

CBT effects in relation to the timing of follow-up assessment were examined in the present review. Here, outcomes were pooled at 1- to 6-month follow-up (i.e., early) and at 8 months or later (i.e., late). Further, a minority of early follow-up (Carroll, Rounsaville, & Gawin, 1991; Pappas et al., 2011; Smout et al., 2010; Stephens, Roffman, & Curtin, 2000) and late follow-up (Dawe, Rees, Mattick, Sitharthan, & Heather, 2002; Thornton, Gottheil, Patkar, & Weinstein, 2003) studies provided effect estimates prior to 6 and 12 months, respectively. This underscores the nature of findings in the present study as maintenance of CBT effects at follow-up, rather than initial efficacy at posttreatment. Studies using a no treatment or a minimal treatment contrast provide the optimal conditions for examining the durability of treatment effect. In these cases, studies reporting frequency outcomes demonstrated that CBT effects were quite durable with moderate effects at both early ($k = 5$) and late ($k = 4$) follow-ups. The cognitive-behavioral emphasis on relapse prevention suggests this is a treatment well-suited to abstinence maintenance and long-term functioning. When the contrast condition was a nonspecific or specific therapy, then relative durability in contrast to another form of treatment is the effect measure. This relative durability was not demonstrated in the present review.

Perhaps the most important message of this meta-analysis, in concert with others in the literature, is that contrast condition matters when intervention effect magnitude is of interest (e.g., Wampold, 1997; Wampold, Minami, Baskin, & Callen Tierney, 2002). We suggest that future meta-analyses label effect sizes for exactly what they are, that is, effect sizes in contrast to no treat-

Table 3
Study-Level Predictors of Effect Size Heterogeneity

Predictor	β	<i>b</i>	<i>z</i>	<i>p</i>
Participant block				
Age <i>M</i>	-1.225	-.072	-2.017	.044
Female %	.160	.003	.347	.729
White %	-.728	-.005	-1.314	.189
Primary drug (reference = drug)	.798	.547	1.636	.102
Substance use severity (reference = dependent)	-.470	-.248	-.969	.332
$Q_E (5) = 4.874$				
$Q_R (3) = 1.183$				
Implementation block				
Treatment format (reference = group)	-.191	-.068	-.453	.651
Treatment length	-.708	-.018	-1.681	.093
$Q_E (2) = 2.827$				
$Q_R (6) = 3.229$				
Methodological block				
Risk of bias (reference = low)	-.451	-.232	-1.110	.267
$Q_E (1) = 1.232$				
$Q_R (7) = 4.824$				

Note. $k = 9$. Q_E and Q_R = chi-square explained and residual, respectively. Treatment length was measured in number of planned cognitive-behavioral therapy sessions.

ment, assessment only, or other minimal treatment versus effect sizes in relation to another form of treatment. In the present study, estimates of effect were sizable only among the seven studies contrasting CBT with a minimal comparison. When nonspecific therapies or usual care were the contrast, the pooled effect size was small to nonsignificant. In this review, nonspecific contrasts were typically either treatment as usual (e.g., Bowen et al., 2014; McKay et al., 2010; Morgenstern, Blanchard, Morgan, Labouvie, & Hayaki, 2001; Papas et al., 2011) or conditions designed to account for nonspecific therapy factors (e.g., supportive therapy [Burtscheidt, Wölwer, Schwarz, Strauss, & Gaebel, 2002]; didactic education [Kivlahan et al., 1990]). Modest relative efficacy in contrast to these conditions underscores how little we know about the specificity of CBT ingredients when delivered to populations with alcohol or other drug use disorders. A view of Table 1 in the online supplemental material supports this point where nonspecific contrasts were quite variable, but often involved addiction information, mutual support, and 12-step program involvement. These are established elements of community-based care and confer benefit (Substance Abuse and Mental Health Services Administration, 2017).

Nonsignificant pooled effects, in contrast to a specific therapy, across outcome types and follow-up time point was observed in the present study. As noted in the preceding text, this type of contrast characterized most studies reviewed despite the known phenomenon of limited evidence for differential efficacy between specific therapies (i.e., “the dodo bird effect”). Although it is beyond the scope of this work, an important question for future research is - how or why this phenomenon continues to occur? A range of explanations have been offered including common factors and specific, yet equally effective, factors (e.g., Magill, Kiluk, McCrady, Tonigan, & Longabaugh, 2015), and it could be a combination of both. Such questions are complex, but highly significant for future clinical training, intervention refinement, and community program implementation.

The limitations of this study may reflect some of the key trade-offs in meta-analysis. Specifically, our primary goal was to derive valid, random effects estimates characterized by effect modifiers. In other words, the study sought to avoid combining “apples and oranges” (Wilson, 2000). The trade-off was that some effect estimates were comprised of a small number of primary studies, which could result in underpowered moderator analysis if heterogeneity was present in these pooled effects. In this study, two of 10 subgroup effect sizes showed greater than 40% systematic heterogeneity, and one of these two subgroups had a sufficient number of studies to allow multivariate moderator analysis. CBT frequency outcomes at early follow-up, in contrast to a nonspecific therapy, showed smaller effect sizes among studies with older samples. In summary, the derived effect sizes showed minimal heterogeneity, and when heterogeneity was observed, moderator analyses revealed few significant moderating factors possibly due to low statistical power.

Additional limitations are perhaps more conceptual than statistical, but nevertheless reflect potential challenges to the validity of meta-analytic studies of intervention efficacy. The first concerns fidelity and other sources of variability in what comprised the sample of CBT interventions. As noted, we sought homogeneity in how CBT was defined via inclusion of face-to-face CBT not combined with another intervention, whether psychosocial or phar-

macological. However, reporting of therapist training (44%), supervision frequency and/or methods (70%), and fidelity (7%) was variable in the sample of studies. As such, the quality of CBT-delivery cannot be assured. Second, study results should be considered in the context of the ongoing debate about what constitutes an optimal outcome in randomized clinical trials with substance use disorders. We selected consumption measures, and favored biological assay variables, but equally meaningful are use consequences and improvements in overall functioning (Kiluk, Fitzmaurice, Strain, & Weiss, 2019). Further, optimal outcomes could vary as a function of intervention modality, including specific ingredients and purported mechanisms of action (Donovan et al., 2012). Therefore, the degree to which the outcomes presented in this review reflect an ideal endpoint or merely one kind of endpoint for measurement of CBT efficacy should be considered.

Conclusion

In conclusion, this meta-analysis shows CBT efficacy, in contrast to no or minimal treatment, was moderate and durable over follow-up. Consistent with several evidence-based addictions therapies, CBT effect sizes were small to nonsignificant in contrast to nonspecific and specific therapies, respectively. Most derived effects were homogeneous, suggesting that the selected subgroup variables (i.e., contrast type, outcome type, and follow-up time point) were informative modifiers of CBT effects.⁵

⁵ Please see the online supplemental material for the PRISMA Checklist.

References

References marked with an asterisk indicate studies included in the meta-analysis.

- American Psychiatric Association. (1987). *Diagnostic and statistical manual of mental disorders* (3rd ed., test rev.). Washington, DC: Author.
- American Psychiatric Association. (1994). *Diagnostic and statistical manual of mental disorders* (4th ed.). Washington, DC: Author.
- American Psychiatric Association. (2000). *Diagnostic and statistical manual of mental disorders* (4th ed., text rev.). Washington, DC: Author.
- American Psychiatric Association. (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.). Washington, DC: Author.
- Baujat, B., Mahé, C., Pignon, J. P., & Hill, C. (2002). A graphical method for exploring heterogeneity in meta-analyses: Application to a meta-analysis of 65 trials. *Statistics in Medicine*, *21*, 2641–2652. <http://dx.doi.org/10.1002/sim.1221>
- Begg, C. B., & Mazumdar, M. (1994). Operating characteristics of a rank correlation test for publication bias. *Biometrics*, *50*, 1088–1101. <http://dx.doi.org/10.2307/2533446>
- Bertholet, N., Daepfen, J. B., Wietlisbach, V., Fleming, M., & Burnand, B. (2005). Reduction of alcohol consumption by brief alcohol intervention in primary care: Systematic review and meta-analysis. *Archives of Internal Medicine*, *165*, 986–995. <http://dx.doi.org/10.1001/archinte.165.9.986>
- Borenstein, M., Hedges, L., Higgins, J., & Rothstein, H. (2015). *Regression in meta-analysis*. Retrieved from <https://www.meta-analysis.com/downloads/MRManual.pdf>
- *Bowen, S., Witkiewitz, K., Clifasefi, S. L., Grow, J., Chawla, N., Hsu, S. H., . . . Larimer, M. E. (2014). Relative efficacy of mindfulness-based relapse prevention, standard relapse prevention, and treatment as usual for substance use disorders: A randomized clinical trial. *Journal of the*

- American Medical Association Psychiatry*, 71, 547–556. <http://dx.doi.org/10.1001/jamapsychiatry.2013.4546>
- *Brown, T. G., Seraganian, P., Tremblay, J., & Annis, H. (2002). Matching substance abuse aftercare treatments to client characteristics. *Addictive Behaviors*, 27, 585–604. [http://dx.doi.org/10.1016/S0306-4603\(01\)00195-2](http://dx.doi.org/10.1016/S0306-4603(01)00195-2)
- *Budney, A. J., Moore, B. A., Rocha, H. L., & Higgins, S. T. (2006). Clinical trial of abstinence-based vouchers and cognitive-behavioral therapy for cannabis dependence. *Journal of Consulting and Clinical Psychology*, 74, 307–316. <http://dx.doi.org/10.1037/0022-006X.74.2.307>
- *Burtscheidt, W., Wölwer, W., Schwarz, R., Strauss, W., & Gaebel, W. (2002). Out-patient behaviour therapy in alcoholism: Treatment outcome after 2 years. *Acta Psychiatrica Scandinavica*, 106, 227–232. <http://dx.doi.org/10.1034/j.1600-0447.2002.02332.x>
- Butler, A. C., Chapman, J. E., Forman, E. M., & Beck, A. T. (2006). The empirical status of cognitive-behavioral therapy: A review of meta-analyses. *Clinical Psychology Review*, 26, 17–31. <http://dx.doi.org/10.1016/j.cpr.2005.07.003>
- Carroll, K. M. (1996). Relapse prevention as a psychosocial treatment: A review of controlled clinical trials. *Experimental and Clinical Psychopharmacology*, 4, 46–54. <http://dx.doi.org/10.1037/1064-1297.4.1.46>
- Carroll, K. M. (1998). *A cognitive behavioral approach: Treating cocaine addiction (NIH Publication No. 984308)*. Rockville, MD: National Institute on Drug Abuse.
- Carroll, K. M., & Kiluk, B. D. (2017). Cognitive behavioral interventions for alcohol and drug use disorders: Through the stage model and back again. *Psychology of Addictive Behaviors*, 31, 847–861. <http://dx.doi.org/10.1037/adb0000311>
- Carroll, K. M., & Onken, L. S. (2005). Behavioral therapies for drug abuse. *The American Journal of Psychiatry*, 162, 1452–1460. <http://dx.doi.org/10.1176/appi.ajp.162.8.1452>
- *Carroll, K. M., Rounsaville, B. J., & Gawin, F. H. (1991). A comparative trial of psychotherapies for ambulatory cocaine abusers: Relapse prevention and interpersonal psychotherapy. *The American Journal of Drug and Alcohol Abuse*, 17, 229–247. <http://dx.doi.org/10.3109/00952999109027549>
- Cohen, J. (1988). The effect size index: *D*. In J. Cohen (Ed.), *Statistical power analysis for the behavioral sciences* (Vol. 2, pp. 284–288). Mahwah, NJ: Erlbaum.
- *Dawe, S., Rees, V. W., Mattick, R., Sitharthan, T., & Heather, N. (2002). Efficacy of moderation-oriented cue exposure for problem drinkers: A randomized controlled trial. *Journal of Consulting and Clinical Psychology*, 70, 1045–1050. <http://dx.doi.org/10.1037/0022-006X.70.4.1045>
- Donovan, D. M., Bigelow, G. E., Brigham, G. S., Carroll, K. M., Cohen, A. J., Gardin, J. G., . . . Wells, E. A. (2012). Primary outcome indices in illicit drug dependence treatment research: Systematic approach to selection and measurement of drug use end-points in clinical trials. *Addiction*, 107, 694–708. <http://dx.doi.org/10.1111/j.1360-0443.2011.03473.x>
- *Donovan, D. M., & Ito, J. R. (1988). Cognitive behavioral relapse prevention strategies and aftercare in alcoholism rehabilitation. *Psychology of Addictive Behaviors*, 2, 74–81. <http://dx.doi.org/10.1037/h0080521>
- Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008). A meta-analytic review of psychosocial interventions for substance use disorders. *The American Journal of Psychiatry*, 165, 179–187. <http://dx.doi.org/10.1176/appi.ajp.2007.06111851>
- Egger, M., Davey Smith, G., Schneider, M., & Minder, C. (1997). Bias in meta-analysis detected by a simple, graphical test. *British Medical Journal*, 315, 629–634. <http://dx.doi.org/10.1136/bmj.315.7109.629>
- Epstein, E. E., & McCrady, B. S. (2009). *A cognitive-behavioral treatment program for overcoming alcohol problems: Therapist guide*. New York, NY: Oxford University Press. <http://dx.doi.org/10.1093/med/psych/9780195322811.001.0001>
- Fullerton, C. A., Kim, M., Thomas, C. P., Lyman, D. R., Montejano, L. B., Dougherty, R. H., . . . Delphin-Rittmon, M. E. (2014). Medication-assisted treatment with methadone: Assessing the evidence. *Psychiatric Services*, 65, 146–157. <http://dx.doi.org/10.1176/appi.ps.201300235>
- *Heather, N., Brodie, J., Wale, S., Wilkinson, G., Luce, A., Webb, E., & McCarthy, S. (2000). A randomized controlled trial of moderation-oriented cue exposure. *Journal of Studies on Alcohol*, 61, 561–570. <http://dx.doi.org/10.15288/jsa.2000.61.561>
- Hedges, L. V. (1994). Statistical considerations. In H. Cooper & L. V. Hedges (Eds.), *The handbook of research synthesis* (pp. 29–38). New York, NY: Russell Sage Foundation.
- Hedges, L. V., & Olkin, I. (1985). *Statistical methods for meta-analysis*. San Diego, CA: Academic Press.
- Hedges, L. V., & Vevea, J. L. (1998). Fixed-and random-effects models in meta-analysis. *Psychological Methods*, 3, 486–504. <http://dx.doi.org/10.1037/1082-989X.3.4.486>
- Higgins, J. P., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., . . . the Cochrane Statistical Methods Group. (2011). The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *British Medical Journal*, 343, d5928. <http://dx.doi.org/10.1136/bmj.d5928>
- Higgins, J. P. T., & Green, S. (Eds.). (2011). *Cochrane handbook for systematic reviews of interventions* (Version 5.1.0 [updated March 2011]). *The Cochrane Collaboration*. Retrieved from <http://handbook-5-1.cochrane.org/>
- Hofmann, S. G., Asnaani, A., Vonk, I. J., Sawyer, A. T., & Fang, A. (2012). The efficacy of cognitive behavioral therapy: A review of meta-analyses. *Cognitive Therapy and Research*, 36, 427–440. <http://dx.doi.org/10.1007/s10608-012-9476-1>
- IBM Corp. (2016). *IBM statistics for windows* (Version 24.0) [Computer Software]. Armonk, NY: Author.
- Imel, Z. E., Wampold, B. E., Miller, S. D., & Fleming, R. R. (2008). Distinctions without a difference: Direct comparisons of psychotherapies for alcohol use disorders. *Psychology of Addictive Behaviors*, 22, 533–543. <http://dx.doi.org/10.1037/a0013171>
- Irvin, J. E., Bowers, C. A., Dunn, M. E., & Wang, M. C. (1999). Efficacy of relapse prevention: A meta-analytic review. *Journal of Consulting and Clinical Psychology*, 67, 563–570. <http://dx.doi.org/10.1037/0022-006X.67.4.563>
- *Jones, S. L., Kanfer, R., & Lanyon, R. I. (1982). Skill training with alcoholics: A clinical extension. *Addictive Behaviors*, 7, 285–290. [http://dx.doi.org/10.1016/0306-4603\(82\)90057-0](http://dx.doi.org/10.1016/0306-4603(82)90057-0)
- Kadden, R. M., Carroll, K., Donovan, D., Cooney, N., Monti, P., Abrams, D., . . . Hester, R. (Eds.). (1992). *Cognitive-behavioral coping skills therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence*. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism.
- *Kadden, R. M., Cooney, N. L., Getter, H., & Litt, M. D. (1989). Matching alcoholics to coping skills or interactional therapies: Posttreatment results. *Journal of Consulting and Clinical Psychology*, 57, 698–704. <http://dx.doi.org/10.1037/0022-006X.57.6.698>
- *Kadden, R. M., Litt, M. D., Cooney, N. L., Kabela, E., & Getter, H. (2001). Prospective matching of alcoholic clients to cognitive-behavioral or interactional group therapy. *Journal of Studies on Alcohol*, 62, 359–369. <http://dx.doi.org/10.15288/jsa.2001.62.359>
- Källmén, H., Sjöberg, L., & Wennberg, P. (2003). The effect of coping skills training on alcohol consumption in heavy social drinking. *Substance Use & Misuse*, 38, 895–903. <http://dx.doi.org/10.1081/JA-120017616>
- Kiluk, B. D., Fitzmaurice, G. M., Strain, E. C., & Weiss, R. D. (2019). What defines a clinically meaningful outcome in the treatment of substance use disorders: Reductions in direct consequences of drug use or improvement in overall functioning? *Addiction*, 114, 9–15. <http://dx.doi.org/10.1111/add.14289>

- *Kivlahan, D. R., Marlatt, G. A., Fromme, K., Coppel, D. B., & Williams, E. (1990). Secondary prevention with college drinkers: Evaluation of an alcohol skills training program. *Journal of Consulting and Clinical Psychology, 58*, 805–810. <http://dx.doi.org/10.1037/0022-006X.58.6.805>
- *Lanza, P. V., García, P. F., Lamelas, F. R., & González-Menéndez, A. (2014). Acceptance and commitment therapy versus cognitive behavioral therapy in the treatment of substance use disorder with incarcerated women. *Journal of Clinical Psychology, 70*, 644–657. <http://dx.doi.org/10.1002/jclp.22060>
- Lipsey, M. W., & Wilson, D. B. (2001). *Practical meta-analysis*. Thousand Oaks, CA: SAGE.
- *Litt, M. D., Kadden, R. M., Tennen, H., & Kabela-Cormier, E. (2016). Network Support II: Randomized controlled trial of Network Support treatment and cognitive behavioral therapy for alcohol use disorder. *Drug and Alcohol Dependence, 165*, 203–212. <http://dx.doi.org/10.1016/j.drugalcdep.2016.06.010>
- Longabaugh, R., & Morgenstern, J. (1999). Cognitive-behavioral coping-skills therapy for alcohol dependence. Current status and future directions. *Alcohol Research & Health, 23*, 78–85.
- Lundahl, B. W., Kunz, C., Brownell, C., Tollefson, D., & Burke, B. L. (2010). A meta-analysis of motivational interviewing: Twenty-five years of empirical studies. *Research on Social Work Practice, 20*, 137–160. <http://dx.doi.org/10.1177/1049731509347850>
- Magill, M., Kiluk, B. D., McCrady, B. S., Tonigan, J. S., & Longabaugh, R. (2015). Active ingredients of treatment and client mechanisms of change in behavioral treatments for alcohol use disorders: Progress 10 years later. *Alcoholism: Clinical and Experimental Research, 39*, 1852–1862. <http://dx.doi.org/10.1111/acer.12848>
- Magill, M., & Ray, L. A. (2009). Cognitive-behavioral treatment with adult alcohol and illicit drug users: A meta-analysis of randomized controlled trials. *Journal of Studies on Alcohol and Drugs, 70*, 516–527. <http://dx.doi.org/10.15288/jsad.2009.70.516>
- Maisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013). Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: When are these medications most helpful? *Addiction, 108*, 275–293. <http://dx.doi.org/10.1111/j.1360-0443.2012.04054.x>
- Marlatt, G. A., & Gordon, J. R. (Eds.). (1985). *Relapse prevention: Maintenance strategies in the treatment of addictive behaviors*. New York, NY: Guilford Press.
- Mastroleo, N. R., & Monti, P. M. (2013). Cognitive-behavioral treatment for addictions. In B. S. McCrady & E. E. Epstein (Eds.), *Addictions: A comprehensive guidebook* (pp. 391–410). New York, NY: Oxford University Press.
- *Maude-Griffin, P. M., Hohenstein, J. M., Humfleet, G. L., Reilly, P. M., Tusel, D. J., & Hall, S. M. (1998). Superior efficacy of cognitive-behavioral therapy for urban crack cocaine abusers: Main and matching effects. *Journal of Consulting and Clinical Psychology, 66*, 832–837. <http://dx.doi.org/10.1037/0022-006X.66.5.832>
- *McAuliffe, W. E. (1990). A randomized controlled trial of recovery training and self-help for opioid addicts in New England and Hong Kong. *Journal of Psychoactive Drugs, 22*, 197–209. <http://dx.doi.org/10.1080/02791072.1990.10472544>
- McHugh, R. K., Hearon, B. A., & Otto, M. W. (2010). Cognitive behavioral therapy for substance use disorders. *Psychiatry Clinica, 33*, 511–525.
- *McKay, J. R., Alterman, A. I., Cacciola, J. S., Rutherford, M. J., O'Brien, C. P., & Koppenhaver, J. (1997). Group counseling versus individualized relapse prevention aftercare following intensive outpatient treatment for cocaine dependence: Initial results. *Journal of Consulting and Clinical Psychology, 65*, 778–788. <http://dx.doi.org/10.1037/0022-006X.65.5.778>
- *McKay, J. R., Lynch, K. G., Coviello, D., Morrison, R., Cary, M. S., Skalina, L., & Plebani, J. (2010). Randomized trial of continuing care enhancements for cocaine-dependent patients following initial engagement. *Journal of Consulting and Clinical Psychology, 78*, 111–120. <http://dx.doi.org/10.1037/a0018139>
- *McKay, J. R., Lynch, K. G., Shepard, D. S., Ratichek, S., Morrison, R., Koppenhaver, J., & Pettinati, H. M. (2004). The effectiveness of telephone-based continuing care in the clinical management of alcohol and cocaine use disorders: 12-month outcomes. *Journal of Consulting and Clinical Psychology, 72*, 967–979. <http://dx.doi.org/10.1037/0022-006X.72.6.967>
- McLellan, A. T., Luborsky, L., Woody, G. E., & O'Brien, C. P. (1980). An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. *Journal of Nervous and Mental Disease, 168*, 26–33. <http://dx.doi.org/10.1097/00005053-198001000-00006>
- Miller, W. R., Wilbourne, P. L., & Hettema, J. E. (2003). What works? A summary of alcohol treatment outcome research. summary of alcohol treatment outcome research. In R. K. Hester & W. R. Miller (Eds.), *Handbook of alcohol treatment approaches: Effective alternatives* (3rd ed., pp. 13–63). Boston, MA: Allyn & Bacon.
- Moher, D., Cook, D. J., Eastwood, S., Olkin, I., Rennie, D., & Stroup, D. F. (1999). Improving the quality of reports of meta-analyses of randomised controlled trials: The QUORUM statement. *Lancet, 354*, 1896–1900. [http://dx.doi.org/10.1016/S0140-6736\(99\)04149-5](http://dx.doi.org/10.1016/S0140-6736(99)04149-5)
- Monti, P. M., Abrams, D. B., Kadden, R. M., & Cooney, N. L. (1989). *Treating alcohol dependence: A coping skills training guide*. New York, NY: Guilford Press.
- *Monti, P. M., Rohsenow, D. J., Michalec, E., Martin, R. A., & Abrams, D. B. (1997). Brief coping skills treatment for cocaine abuse: Substance use outcomes at three months. *Addiction, 92*, 1717–1728. <http://dx.doi.org/10.1111/j.1360-0443.1997.tb02892.x>
- *Morgenstern, J., Blanchard, K. A., Morgan, T. J., Labouvie, E., & Hayaki, J. (2001). Testing the effectiveness of cognitive-behavioral treatment for substance abuse in a community setting: Within treatment and posttreatment findings. *Journal of Consulting and Clinical Psychology, 69*, 1007–1017. <http://dx.doi.org/10.1037/0022-006X.69.6.1007>
- *Papas, R. K., Sidle, J. E., Gakinya, B. N., Baliddawa, J. B., Martino, S., Mwaniki, M. M., . . . Maisto, S. A. (2011). Treatment outcomes of a stage I cognitive-behavioral trial to reduce alcohol use among human immunodeficiency virus-infected out-patients in western Kenya. *Addiction, 106*, 2156–2166. <http://dx.doi.org/10.1111/j.1360-0443.2011.03518.x>
- Pigott, T. D. (1994). Methods for handling missing data in research synthesis. In H. Cooper & L. V. Hedges (Eds.), *The handbook of research synthesis* (pp. 163–175). New York, NY: Russell Sage Foundation.
- Prendergast, M. L., Podus, D., Chang, E., & Urada, D. (2002). The effectiveness of drug abuse treatment: A meta-analysis of comparison group studies. *Drug and Alcohol Dependence, 67*, 53–72. [http://dx.doi.org/10.1016/S0376-8716\(02\)00014-5](http://dx.doi.org/10.1016/S0376-8716(02)00014-5)
- *Project MATCH Research Group. (1997). Matching alcoholism treatments to client heterogeneity: Project MATCH posttreatment drinking outcomes. *Journal of Studies on Alcohol, 58*, 7–29. <http://dx.doi.org/10.15288/jsa.1997.58.7>
- *Sandahl, C., Gerge, A., & Herlitz, K. (2004). Does treatment focus on self-efficacy result in better coping? Paradoxical findings from psychodynamic and cognitive-behavioral group treatment of moderately alcohol-dependent patients. *Psychotherapy Research, 14*, 388–397. <http://dx.doi.org/10.1093/ptr/kph032>
- Saunders, J. B., Aasland, O. G., Babor, T. F., de la Fuente, J. R., & Grant, M. (1993). Development of the alcohol use disorders identification test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. *Addiction, 88*, 791–804. <http://dx.doi.org/10.1111/j.1360-0443.1993.tb02093.x>

- *Shakeshaft, A. P., Bowman, J. A., Burrows, S., Doran, C. M., & Sanson-Fisher, R. W. (2002). Community-based alcohol counselling: A randomized clinical trial. *Addiction*, *97*, 1449–1463. <http://dx.doi.org/10.1046/j.1360-0443.2002.00199.x>
- *Sitharthan, T., Sitharthan, G., Hough, M. J., & Kavanagh, D. J. (1997). Cue exposure in moderation drinking: A comparison with cognitive-behavior therapy. *Journal of Consulting and Clinical Psychology*, *65*, 878–882. <http://dx.doi.org/10.1037/0022-006X.65.5.878>
- *Smout, M. F., Longo, M., Harrison, S., Minniti, R., Wickes, W., & White, J. M. (2010). Psychosocial treatment for methamphetamine use disorders: A preliminary randomized controlled trial of cognitive behavior therapy and acceptance and commitment therapy. *Substance Abuse*, *31*, 98–107. <http://dx.doi.org/10.1080/08897071003641578>
- *Stephens, R. S., Roffman, R. A., & Curtin, L. (2000). Comparison of extended versus brief treatments for marijuana use. *Journal of Consulting and Clinical Psychology*, *68*, 898–908. <http://dx.doi.org/10.1037/0022-006X.68.5.898>
- *Stephens, R. S., Roffman, R. A., & Simpson, E. E. (1994). Treating adult marijuana dependence: A test of the relapse prevention model. *Journal of Consulting and Clinical Psychology*, *62*, 92–99. <http://dx.doi.org/10.1037/0022-006X.62.1.92>
- Streeton, C., & Whelan, G. (2001). Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: A meta-analysis of randomized controlled trials. *Alcohol and Alcoholism*, *36*, 544–552. <http://dx.doi.org/10.1093/alcac/36.6.544>
- Substance Abuse and Mental Health Services Administration. (2014). *The national survey of substance abuse treatment services (N-SSATS)*. Rockville, MD: U. S. Department of Health and Human Services.
- Substance Abuse and Mental Health Services Administration. (2017). *Addiction counseling competencies (TAP-21)*. Rockville, MD: U. S. Department of Health and Human Services.
- Tanner-Smith, E. E., Durlak, J. A., & Marx, R. A. (2018). Empirically based mean effect size distributions for universal prevention programs targeting school-aged youth: A review of meta-analyses. *Prevention Science*, *19*, 1091–1101. <http://dx.doi.org/10.1007/s11121-018-0942-1>
- *Thornton, C., Gottheil, E., Patkar, A., & Weinstein, S. (2003). Coping styles and response to high versus low-structure individual counseling for substance abuse. *The American Journal on Addictions*, *12*, 29–42. <http://dx.doi.org/10.1111/j.1521-0391.2003.tb00537.x>
- Wallace, B. C., Small, K., Brodley, C. E., Lau, J., & Trikalinos, T. A. (2012). Deploying an interactive machine learning system in an evidence-based practice center: Abstract. *Proceedings of the 2nd ACM SIGHIT International Health Informatics Symposium* (pp. 819–824). New York, NY: Association for Computing Machinery.
- Wampold, B. E. (1997). Methodological problems in identifying efficacious psychotherapies. *Psychotherapy Research*, *7*, 21–43. <http://dx.doi.org/10.1080/10503309712331331853>
- Wampold, B. E. (2001). *The great psychotherapy debate: Models, methods, and findings*. Mahwah, NJ: Lawrence Erlbaum. <http://dx.doi.org/10.4324/9780203893340>
- Wampold, B. E., & Imel, Z. E. (2015). *The great psychotherapy debate: The evidence for what makes psychotherapy work*. New York, NY: Routledge. <http://dx.doi.org/10.4324/9780203582015>
- Wampold, B. E., Minami, T., Baskin, T. W., & Callen Tierney, S. (2002). A meta-(re)analysis of the effects of cognitive therapy versus ‘other therapies’ for depression. *Journal of Affective Disorders*, *68*(2–3), 159–165. [http://dx.doi.org/10.1016/S0165-0327\(00\)00287-1](http://dx.doi.org/10.1016/S0165-0327(00)00287-1)
- Wampold, B. E., Mondin, G. W., Moody, M., Stich, F., Benson, K., & Ahn, H. N. (1997). A meta-analysis of outcome studies comparing bona fide psychotherapies: Empirically, “all must have prizes”. *Psychological Bulletin*, *122*, 203–215. <http://dx.doi.org/10.1037/0033-2909.122.3.203>
- Wilson, D. B. (2000). Meta-analyses in alcohol and other drug abuse treatment research. *Addiction*, *95*(11s3), 419–438. <http://dx.doi.org/10.1046/j.1360-0443.95.11s3.9.x>
- Wilson, D. B. (2005). *Macros for SPSS/Win Version 6.1 or higher* (Version 2005.05.23). Retrieved from <http://mason.gmu.edu/~dwilsonb/ma.html>

Received April 16, 2019

Revision received August 9, 2019

Accepted August 17, 2019 ■